At its Israeli R&D center, C2i Genomics has developed a personalized, real-time solution for monitoring recurrence and treatment response for various types of solid cancers. It employs a breakthrough tumor DNA pattern recognition approach for liquid biopsy.
Monitoring cancer post-surgery
This entry was posted in Israel's Medical Achievements. Bookmark the permalink.